Procarbazine in Treating Patients With Recurrent Brain Tumor
Brain and Central Nervous System Tumors
About this trial
This is an interventional treatment trial for Brain and Central Nervous System Tumors focused on measuring recurrent adult brain tumor, adult glioblastoma, adult anaplastic astrocytoma, adult anaplastic oligodendroglioma, adult giant cell glioblastoma, adult gliosarcoma
Eligibility Criteria
DISEASE CHARACTERISTICS: Histologically proven malignant glioma of one of the following types: Anaplastic astrocytoma Anaplastic oligodendroglioma Glioblastoma multiforme Progressive or recurrent disease after radiotherapy with or without chemotherapy Measurable disease by serial MR or CT PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60-100% Life expectancy: Greater than 2 months Hematopoietic: Absolute neutrophil count at least 1500/mm^3 Platelet count at least 100,000/mm^3 Hepatic: Bilirubin no greater than 1.5 mg/dL SGPT/SGOT no greater than 4 times upper limit of normal Renal: Creatinine no greater than 1.7 mg/dL Other: No serious concurrent infection No other illness that would preclude study Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception No prior malignancy within the past 5 years except curatively treated basal cell skin cancer or carcinoma in situ of the cervix PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent filgrastim (G-CSF) during the first course Chemotherapy: See Disease Characteristics No more than 1 prior chemotherapy regimen At least 3 weeks since prior chemotherapy (at least 6 weeks since prior nitrosoureas) No more than 2 prior courses of carmustine or lomustine and no greater than 460 mg/m2 or 220 mg/m2, respectively No prior procarbazine Endocrine therapy: Not specified Radiotherapy: See Disease Characteristics At least 3 months since prior radiotherapy Surgery: Prior surgery allowed Other: Recovered from toxicity of prior therapy At least 10 days since prior anticonvulsants for patients in Arm II No concurrent investigational agents No concurrent ethanol, ephedrine, isoproterenol, epinephrine, tricyclic antidepressants, paragyliline, narcotic analgesics, antihistamines, phenothiazines, hypotensives, or barbiturates At least 14 days since prior antidepressants (e.g., SSRI and/or MAO inhibitor) Must avoid foods high in tyramine (i.e., dark beer, wine, yogurt, cheese, bananas)
Sites / Locations
- University of Alabama at Birmingham Comprehensive Cancer Center
- H. Lee Moffitt Cancer Center and Research Institute
- Emory University Hospital - Atlanta
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Massachusetts General Hospital Cancer Center
- Henry Ford Hospital
- Comprehensive Cancer Center at Wake Forest University
- Cleveland Clinic Taussig Cancer Center
- University of Pennsylvania Cancer Center
- University of Texas Health Science Center at San Antonio